Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)

Video

Binod Dhakal, MD, MS, discusses the management of relapsed multiple myeloma and the various treatment options available.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
      Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple Myeloma
      4 experts are featured in this series.
      Real World Experience of CAR-T in MM Patients
      4 experts are featured in this series.
      Importance of Multidisciplinary Approach in Care of CAR-T MM Patients
      4 experts are featured in this series.
      Overview of the Efficacy of Cilta-cel in the CARTITUDE Trials
      4 experts are featured in this series.
      Future Perspectives: What’s Next in NDMM?
      4 experts are featured in this series.
      Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
      4 experts are featured in this series.
      Jackson’s Journey with High Risk R/R MM
      4 experts are featured in this series.
      Role of Bridging Therapy for CAR-T Patients
      4 experts are featured in this series.
      Expert Perspectives: Navigating Between CEPHEUS and IMROZ Studies
      4 experts are featured in this series.
      Transplant-Ineligible NDMM: When to Use a Quadruplet Regimen
      Related Content
      Daratumumab Plus KRd May Be a New SOC Option in NDMM

      Daratumumab Plus KRd May Be a New SOC Option in NDMM

      Tim Cortese
      June 3rd 2025
      Article

      Daratumumab plus KRd improved MRD-negativity and PFS vs KRd alone in patients with newly diagnosed multiple myeloma.

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

      Samantha Shenoy, NP, MSN
      October 14th 2024
      Podcast

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Subgroup data from the CEPHEUS trial reinforce daratumumab plus bortezomib, lenalidomide, and dexamethasone as a standard of care in this population.

      Daratumumab Combo Improves Outcomes in Transplant-Ineligible NDMM Subgroups

      Russ Conroy
      June 2nd 2025
      Article

      Subgroup data from the CEPHEUS trial reinforce daratumumab plus bortezomib, lenalidomide, and dexamethasone as a standard of care in this population.

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

      James R. Berenson, MD, FACP
      September 30th 2024
      Podcast

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Belantamab Mafodotin Combo Elicits PFS in R/R Multiple Myeloma

      Belantamab Mafodotin Combo Elicits PFS in R/R Multiple Myeloma

      Gina Mauro
      June 2nd 2025
      Article

      PFS was improved with belantamab mafodotin triplet for patients with relapsed/refractory multiple myeloma with high-risk cytogenetics.

      The safety profile of talquetamab continued to show a lower high-grade infection risk relative to other approved anti-BCMA bispecific antibodies.

      Talquetamab Elicits Durable Responses, Survival in R/R Multiple Myeloma

      Roman Fabbricatore
      June 1st 2025
      Article

      The safety profile of talquetamab continued to show a lower high-grade infection risk relative to other approved anti-BCMA bispecific antibodies.